Rebecca Jane Abraham

Dr. Rebecca Jane Abraham


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
RARebecca Jane Abraham
Rebecca Jane Abraham
SASam Abraham
Sam Abraham
ASAndrew J. Stevens
Andrew J. Stevens
SPStephen Page
Stephen Page
AMAdam Mccluskey
Adam Mccluskey
RORyan M. O'HAndley
Ryan M. O'HAndley
Giardia duodenalis is an ubiquitous parasitic pathogen that causes significant morbidity and mortality worldwide. Failures in drug therapy are commonly due to poor patient compliance as a result of the need for repeated administration, off target drug effects and increasing parasite drug resistance. In this study the in vitro efficacy and selectivity of the aminoguanidine compound robenidine and 2 structural analogues against Giardia were determined. After 5 h exposure to each compound the IC50 was as low as 0.2 μM with corresponding MLCs as low as 2.8 μM. This is in contrast to metronidazole which required 24 h to exhibit inhibitory activity. A modified adherence assay, developed for this study, demonstrated that three of the compounds inhibited in vitro adherence of the parasite. The lead compound exhibited rapid giardicidal activity (<5hr). In addition, microscopy studies demonstrated damage to the plasma membrane of trophozoites. In conclusion, a class of aminoguanidines, represented by robenidine, has shown antigiardial activity warranting further investigation.

10 March 2026 in Veterinary Microbiology
Verified
Journal Article
Open access
MRMd Ashiqur Rahman
Md Ashiqur Rahman
RARebecca Jane Abraham
Rebecca Jane Abraham
SASam Abraham
Sam Abraham
DHDavid John Hampson
David John Hampson
Jasim Muhammad UddinJasim Muhammad Uddin
Jasim Muhammad Uddin
Bacteriophages (phages) are viruses that infect and may kill bacteria. Phage therapy has gained global attention as a possible means to circumvent problems of bacterial antimicrobial resistance (AMR) in food animal production systems. In preparing this overview on the use of phage therapy in terrestrial food animals, 127 published research articles were analysed to obtain a contemporary background on phage therapy, the efficacy of phage administration, research gaps, and future research directions. Most of the published in vivo trials in chickens described administering phages as biocontrol agents, whereas in vivo trials in pigs administered phages as therapeutics. Only a few trials were conducted in cattle and sheep, targeting foodborne, udder and skin infections. The most common target bacteria in poultry trials were Salmonella Enteritidis, followed by Escherichia coli, Salmonella Typhimurium, Salmonella Pullorum, and Campylobacter jejuni. In contrast, antimicrobial resistant strains of S. Typhimurium and E. coli were the target bacteria in the pig trials. Most studies administered phage cocktails rather than single phage preparation, with bacterial challenge doses varying from 10³ to 10¹⁰ colony forming units (CFU), and phage doses ranging from 10⁵ to 10¹¹ plaque forming units (PFU). In all the reviewed studies phage treatment consistently reduced bacterial load by 0.4-5.0 log₁₀ CFU in feces, meat, and both external and internal organs. Moreover, as a therapeutic, phages were reported to cure diarrhea, improve nutrient digestibility, and enhance weight gain. Phage therapy also reduced specific serum IgG levels against the target bacteria and lowered neutrophil counts and TNF-α concentrations. Together these studies suggest that phage therapy may be an effective treatment approach in controlling certain key infections and hence alleviating bacterial resistance in food animals. Nevertheless, global collaboration and inclusive research on cost-effective production, efficient delivery methods, phage resistance, and host immune responses are essential for overcoming hurdles and facilitating the widespread application of phage therapy in food animals.

8 May 2026 in Viruses
Verified
Journal Article
Open access
PDF file
MRMd Ashiqur Rahman
Md Ashiqur Rahman
RARebecca Jane Abraham
Rebecca Jane Abraham
DHDavid John Hampson
David John Hampson
SASam Abraham
Sam Abraham
Jasim Muhammad UddinJasim Muhammad Uddin
Jasim Muhammad Uddin
Phage therapy has enormous potential in combating bacterial resistance in food animals. However, its application via the oral route remains limited due to challenges associated with the gastrointestinal tract (GIT) environment and a lack of rigorous clinical trial evidence. Therefore, we systematically searched in Google Scholar, PubMed, Scopus, and Web of Science databases following PRISMA guidelines and finally identified 111 articles on oral phage therapy in food animals from where we summarized the key physiological and chemical factors of the gut environment hindering the effectiveness of oral phage therapy (OPT), examined the methods used to evaluate phage stability in the GI environment, and highlighted potential strategies to mitigate these challenges. In addition, we performed quantitative analysis to visualize in vitro pH and thermal stability patterns of phages targeting bacteria isolated from food animals and variability in buffer and incubation period across stability studies. The GIT consists of several anatomically and functionally distinct segments, where complex interactions occur among digestive enzymes, gastric acids, electrolytes, commensal microbiota, and mucosal immune components. The acidic pH of the stomach is a major barrier to successful oral phage delivery. According to our analysis of pH stability testing data from the reviewed studies, most phages targeting antimicrobial-resistant bacteria in food animals remained stable at pH 5–9 and inactivated under highly acidic (pH ≤ 2) or highly alkaline (pH ≥ 11) conditions. In addition, phages are susceptible to high temperatures (above 60 °C), digestive enzymes (e.g., pepsin, trypsin, lipases), bile salts, and host immune responses. Several in vitro laboratory techniques are available to assess phage stability under simulated GI conditions, but variations occur in the assessment protocols. Microencapsulation using alginate and chitosan has been used to protect phages from the adverse GI environment. Additionally, enteric-coated capsules, antacids, co-encapsulation with acid-neutralizing agents, consumption of alkaline water, and daily phage administration are suggested to improve phage survival and efficacy. For the successful clinical implementation of OPT in food animals, future research should focus on elucidating the molecular and physicochemical determinants of phage stability, understanding the humoral immune response to OPT, standardizing laboratory protocol for assessing phage viability, improving the scalability of encapsulation methods, and exploring other potential delivery techniques.

28 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NONikki Owiredu
Nikki Owiredu
SLSoo Sum Lean
Soo Sum Lean
MSMarc Stegger
Marc Stegger
HAHui San Allison
Hui San Allison
KHKylie Hewson
Kylie Hewson
RARebecca Jane Abraham
Rebecca Jane Abraham
The increasing resistance of bacteria to antimicrobials is a major threat to public health. This study investigates the prevalence of antimicrobial resistance, both phenotypic and genotypic, among Campylobacter isolates from Australian meat chickens in 2022, as a follow up to investigate trends since the last national surveillance undertaken in 2016. Isolates (n = 186) were obtained at slaughter from 200 pooled cecal samples taken from 1,000 meat chickens. The majority of C. jejuni (68.7%) and C. coli (88.9%) isolates were susceptible to all the antibiotics that were tested, and no multi-drug resistance was found. Resistance to ciprofloxacin (fluoroquinolone) was detected in 24.4% of the C. jejuni and 3.2% of the C. coli isolates. Whole genome sequencing revealed a diverse range of sequence types (STs). These included 32 previously reported STs for C. jejuni and 13 for C. coli, as well as four and seven previously undescribed STs for each species, respectively. The STs containing fluoroquinolone-resistant isolates were ST2083, ST10130, ST2895, ST7323, ST2398, and ST1078 for C. jejuni, and ST860 and ST894 for C. coli. Although fluoroquinolones are not used in animal production in Australia, resistance amongst C. jejuni isolates was high (24.4%). This finding emphasizes the need for enhanced surveillance and regular sampling along the food chain to understand the source of the isolates and to mitigate risks of antimicrobial resistance to protect public health.

29 September 2022 in ChemMedChem
Verified
Journal Article
Open access
ASAndrew J. Stevens
Andrew J. Stevens
RARebecca Jane Abraham
Rebecca Jane Abraham
KYKelly A. Young
Kelly A. Young
CRCecilia C. Russell
Cecilia C. Russell
SMSiobhann N. McCluskey
Siobhann N. McCluskey
AMAdam Mccluskey
Adam Mccluskey
From four focused compound libraries based on the known anticoccidial agent robenidine, 44 compounds total were synthesised and screened for antigiardial activity. All active compounds were counter‐screened for antibiotic and cytotoxic action. Of the analogues examined, 21 displayed IC50<5 μM, seven with IC50<1.0 μM. Most active were 2,2′‐bis{[4‐(trifluoromethoxy)phenyl]methylene}carbonimidic dihydrazide hydrochloride (30), 2,2′‐bis{[4‐(trifluoromethylsulfanyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (32), and 2,2′‐bis[(2‐bromo‐4,5‐dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (41) with IC50=0.2 μM. The maximal observed activity was a 5 h IC50 value of 0.2 μM for 41. The clinically used metronidazole was inactive at this timepoint at a concentration of 25 μM. Robenidine off‐target effects at bacteria and cell line toxicity were removed. Analogue 41 was well tolerated in mice treated orally (100 mg/kg). Following 5 h treatment with 41, no Giardia regrowth was noted after 48 h.

1 July 2019 in Veterinary Microbiology
Verified
Journal Article
Closed access
SBSkye Badger
Skye Badger
SASam Abraham
Sam Abraham
MOMark O’dEa
Mark O’dEa
SSSugiyono Saputra
Sugiyono Saputra
RARebecca Jane Abraham
Rebecca Jane Abraham
CCCharles G.B. Caraguel
Charles G.B. Caraguel